[go: up one dir, main page]

CN1910165A - 酰基氨基噻唑衍生物及其作为β－淀粉状蛋白抑制剂的用途 - Google Patents

酰基氨基噻唑衍生物及其作为β－淀粉状蛋白抑制剂的用途 Download PDF

Info

Publication number
CN1910165A
CN1910165A CNA2005800025883A CN200580002588A CN1910165A CN 1910165 A CN1910165 A CN 1910165A CN A2005800025883 A CNA2005800025883 A CN A2005800025883A CN 200580002588 A CN200580002588 A CN 200580002588A CN 1910165 A CN1910165 A CN 1910165A
Authority
CN
China
Prior art keywords
group
phenyl
alkyl
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800025883A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴尔策尔
M·帕斯卡尔
V·范多斯莱尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN1910165A publication Critical patent/CN1910165A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005800025883A 2004-01-16 2005-01-07 酰基氨基噻唑衍生物及其作为β－淀粉状蛋白抑制剂的用途 Pending CN1910165A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0400388 2004-01-16
FR0400388A FR2865207B1 (fr) 2004-01-16 2004-01-16 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR0408116 2004-07-22

Publications (1)

Publication Number Publication Date
CN1910165A true CN1910165A (zh) 2007-02-07

Family

ID=34707892

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800025883A Pending CN1910165A (zh) 2004-01-16 2005-01-07 酰基氨基噻唑衍生物及其作为β－淀粉状蛋白抑制剂的用途

Country Status (3)

Country Link
CN (1) CN1910165A (es)
ES (1) ES2369918T3 (es)
FR (1) FR2865207B1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563741B2 (en) 2007-09-10 2013-10-22 Curis, Inc. CDK inhibitors containing a zinc binding moiety

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2345072C1 (ru) * 2007-07-23 2009-01-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) N-(1,3-тиазол-2-ил) амиды 2-дифенилметиленгидразоно-5,5-диметил-2,4-диоксогексановой кислоты, проявляющие противовоспалительную и анальгетическую активность, и способ получения
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
BR0314611A (pt) * 2002-10-09 2005-07-26 Pfizer Prod Inc Compostos de tiazol para o tratamento de distúrbios neurodegenerativos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563741B2 (en) 2007-09-10 2013-10-22 Curis, Inc. CDK inhibitors containing a zinc binding moiety

Also Published As

Publication number Publication date
ES2369918T3 (es) 2011-12-09
FR2865207A1 (fr) 2005-07-22
FR2865207B1 (fr) 2008-10-17

Similar Documents

Publication Publication Date Title
CN1176651C (zh) N-(3-苯并呋喃基)脲衍生物
CN1164573C (zh) 新的α-氨基酸化合物、其制备方法和包含它们的药物组合物
CN1145616C (zh) 新的氨基三唑化合物,其制备方法及包含它们的药物组合物
CN1922161A (zh) 1－哌嗪－和1－高哌嗪－羧酸酯衍生物、制备和其治疗用途
CN1080720C (zh) 噻唑衍生物
CN1639159A (zh) N－氨基乙酰基－吡咯烷－2－腈和它们作为ddp－iv抑制剂的用途
CN1037519A (zh) 杂环酮类
CN1377879A (zh) 新的α－氨基酸磺酰基化合物、其制备方法和含有它们的药物组合物
CN1656077A (zh) 制备手性二醇砜和二羟基酸HMGCoA还原酶抑制剂的方法
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1845909A (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹喔啉衍生物及它们的用途
CN1273456C (zh) 噻唑和噁唑衍生物
CN1921858A (zh) 哌啶基烷基氨基甲酸酯衍生物、其制备方法及其作为faah酶抑制剂的应用
HK1044955A1 (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
CN1852907A (zh) 2－氨基－5－苯甲酰基噻唑npy拮抗剂
CN1777593A (zh) 酰基氨基噻唑衍生物,其制备方法及其作为β－淀粉样肽生产抑制剂的用途
CN1514823A (zh) 草酸衍生物
CN1910165A (zh) 酰基氨基噻唑衍生物及其作为β－淀粉状蛋白抑制剂的用途
CN1860097A (zh) 酰胺型甲酰胺衍生物
CN1211375C (zh) 噻唑衍生物
CN1121384C (zh) 青霉胺酰胺衍生物
CN101039912A (zh) 吡啶衍生物和它们的制备方法及其治疗应用
CN1098849C (zh) 噻唑衍生物
HK1100439A (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
CN1856488A (zh) 氨甲酰型苯并呋喃衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1100439

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20070207

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1100439

Country of ref document: HK